Related Experiment Video
Updated: Nov 6, 2025
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia
Hiroto Inaba1,2, Ching-Hon Pui1,2
1Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Insights
Pediatric acute lymphoblastic leukemia (ALL) survival has greatly improved due to advanced diagnostics and treatments. Future goals focus on near-100% survival and reducing therapy side effects using targeted approaches.
Area of Science:
- Pediatric Oncology
- Hematology
- Molecular Biology
Background:
- Outcomes for pediatric acute lymphoblastic leukemia (ALL) have significantly improved over the past 50 years.
- Advances in diagnostics, chemotherapy, and supportive care have driven these improvements, with survival rates exceeding 90% in high-income nations.
Purpose of the Study:
- To outline the progress in pediatric ALL treatment and survival.
- To discuss future directions for improving outcomes and minimizing treatment toxicity.
- To highlight the role of molecular subtyping and minimal residual disease monitoring.
Main Methods:
- Review of advancements in diagnostic technologies and chemotherapeutic agents.
- Analysis of genome-wide and RNA-sequencing data for ALL classification.
- Evaluation of minimal residual disease detection methods.
Main Results:
- Pediatric ALL survival rates now surpass 90% in high-income countries.
- Genome-wide analyses have identified over 30 distinct ALL subtypes (B-lineage and T-lineage) with prognostic significance.
- Minimal residual disease detection allows for precise monitoring of treatment response.
Conclusions:
- The goal is to achieve near 100% survival for pediatric ALL and reduce treatment-related adverse effects.
- Molecularly targeted therapies and immunotherapies offer promising strategies to refine or replace conventional chemotherapy.
- Personalized treatment based on ALL subtypes and minimal residual disease is the future direction.
Abstract:
The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably during the last five decades. Such improvements were made possible by the incorporation of new diagnostic technologies, the effective administration of conventional chemotherapeutic agents, and the provision of better supportive care. With the 5-year survival rates now exceeding 90% in high-income countries, the goal for the next decade is to improve survival further toward 100% and to minimize treatment-related adverse effects. Based on genome-wide analyses, especially RNA-sequencing analyses, ALL can be classified into more than 20 B-lineage subtypes and more than 10 T-lineage subtypes with prognostic and therapeutic implications. Response to treatment is another critical prognostic factor, and detailed analysis of minimal residual disease can detect levels as low as one ALL cell among 1 million total cells. Such detailed analysis can facilitate the rational use of molecular targeted therapy and immunotherapy, which have emerged as new treatment strategies that can replace or reduce the use of conventional chemotherapy.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...